萬隆控股集團(00030.HK)獲雲南白藥溢價約3.64%提收購要約 明日復牌
格隆匯11月4日丨萬隆控股集團(00030.HK)發佈公吿，於2021年9月9日，新華都香港於二級市場收購5600萬股股份（佔已發行股份約0.87%），代價為每股股份0.285港元。
於2021年10月27日，要約人正式就提出要約通知公司。緊接收購事項前，要約人及其一致行動人士於19.1億股股份（相當於公司全部已發行股本約29.59%）中擁有權益。由於進行收購事項，要約人連同其一致行動人士變為共同於19.64億股股份（相當於緊隨收購事項後及於本聯合公佈日期已發行股份總數約30.46%）中擁有權益。
新華都香港由新華都實業全資擁有，而新華都實業則由陳發樹先生透過彼於廈門新華都的股權及透過彼以個人身份持有的有關股權持有約93.69%權益。陳發樹先生為雲南白藥董事，並連同其一致行動人士持有云南白藥約25.04%權益。要約人云白藥香港有限公司為雲南白藥的間接全資附屬公司。因此，要約人、陳發樹先生、新華都香港、廈門新華都、新華都實業及雲南白藥根據收購守則被推定為一致行動人士。
根據收購守則規則26.1，須就獨立股東持有的所有已發行股份提出強制性有條件全面現金要約。每股要約股份現金0.285港元,較10月27日收市價每股0.275港元溢價約3.64%。
據悉，要約人為一間於香港註冊成立的有限公司，主要從事投資控股。其為雲南白藥的間接全資附屬公司。要約人連同其一致行動人士的意向為，集團將大致在其現況下持續經營其業務。
要約人連同其一致行動人士無意(i)終止僱用僱員或(ii)出售或重新部署本集團的資產（於日常業務過程中除外）。要約人認為，完成要約將可加強雲南白藥集團與集團之間的策略性協同效益，並提升雲南白藥集團的國際形象。考慮到集團在商品貿易方面的豐富經驗及其發展成熟的銷售渠道，要約人相信雲南白藥集團與集團將能透過合作，進一步尋求互惠互利的業務發展機會，並同時令雲南白藥集團得以變現其於集團的投資回報。
此外，公司股票將於2021年11月5日復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
